Moderated by Dean Martha Minow of Harvard Law School, this panel will focus on the impact of the Supreme Court’s recent decision in the Myriad case that naturally occurring DNA cannot be patented. Will this be a boon for patients and a burden for biotech companies? Will sufficient incentive remain for innovation? Will there be any practical change at all?

Panelists

• Eric S. Lander, Director of the Broad Institute of MIT and Harvard, Professor of Biology at MIT, and Professor of Systems Biology at Harvard Medical School
• I. Glenn Cohen, Professor of Law, Harvard Law School; Faculty Co-Director of the Petrie-Flom Center
• Benjamin N. Roin, Hieken Assistant Professor in Patent Law, Harvard Law School; Faculty Co-Director of the Petrie-Flom Center
• Claire Laporte, Partner, Foley Hoag LLP
• Tania Simoncelli, former Science Advisor to the ACLU

Recording

Cosponsored by the Broad Institute of MIT and Harvard.